NASDAQ:NEPH Nephros (NEPH) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free NEPH Stock Alerts $2.19 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$2.19▼$2.1950-Day Range$1.99▼$3.7252-Week Range$1.13▼$4.04Volume476 shsAverage Volume14,162 shsMarket Capitalization$23.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Nephros alerts: Email Address Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. About Nephros Stock (NASDAQ:NEPH)Nephros, Inc. engages in development and sale of high performance water solutions to the medical and commercial markets in the United States. The company operates in two segments: Water Filtration and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells medical device products for patients with renal disease, including a second generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it manufactures and sells water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and Nanoguard brands for the food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Read More NEPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEPH Stock News HeadlinesApril 23, 2024 | finance.yahoo.comNephros to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024April 20, 2024 | finance.yahoo.comNephros, Inc. (NEPH) Interactive Stock Chart - Yahoo FinanceApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.April 19, 2024 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) Profit OutlookApril 16, 2024 | americanbankingnews.comNephros (NASDAQ:NEPH) Shares Down 0.5% March 11, 2024 | finanznachrichten.deNephros, Inc.: Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 10, 2024 | finance.yahoo.comNephros Full Year 2023 Earnings: Misses ExpectationsMarch 9, 2024 | markets.businessinsider.comNephros Poised for Growth: A Buy Recommendation Amid Expansion and Optimized OperationsApril 26, 2024 | Stansberry Research (Ad)World’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.March 9, 2024 | markets.businessinsider.comNephros Poised for Growth: Strong Financials and Strategic Initiatives Secure Buy RatingMarch 8, 2024 | realmoney.thestreet.comNephros just upgraded at Benchmark, here's whyMarch 8, 2024 | finance.yahoo.comNephros, Inc. (NASDAQ:NEPH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.comNEPH Stock Earnings: Nephros Misses EPS, Misses Revenue for Q4 2023March 7, 2024 | globenewswire.comNephros Announces Fourth Quarter and Fiscal Year 2023 Financial ResultsMarch 6, 2024 | benzinga.comEarnings Outlook For NephrosMarch 6, 2024 | markets.businessinsider.comNephros earnings: here's what to expectFebruary 29, 2024 | globenewswire.comNephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial ResultsJanuary 28, 2024 | finance.yahoo.comWhat Is Nephros, Inc.'s (NASDAQ:NEPH) Share Price Doing?January 24, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerJanuary 24, 2024 | finance.yahoo.comRezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial OfficerDecember 18, 2023 | finance.yahoo.comNephros, Inc.'s (NASDAQ:NEPH) P/S Is Still On The Mark Following 40% Share Price BounceDecember 14, 2023 | morningstar.comNephros Inc NEPHDecember 13, 2023 | finance.yahoo.comAre Investors Undervaluing Nephros, Inc. (NASDAQ:NEPH) By 45%?December 12, 2023 | msn.comNephros CEO buys 18k shares of the company - filingDecember 12, 2023 | msn.comTraeger heats up after attracting bull rating from B. RileyNovember 27, 2023 | msn.comNephros (NEPH) Price Target Increased by 50.00% to 4.59November 22, 2023 | markets.businessinsider.comBenchmark Co. Keeps Their Hold Rating on Nephros (NEPH)See More Headlines Receive NEPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nephros and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/25/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NEPH CUSIPN/A CIK1196298 Webwww.nephros.com Phone(201) 343-5202Fax201-343-5207Employees31Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,580,000.00 Net Margins-11.06% Pretax Margin-11.06% Return on Equity-18.25% Return on Assets-14.29% Debt Debt-to-Equity RatioN/A Current Ratio3.98 Quick Ratio2.81 Sales & Book Value Annual Sales$14.24 million Price / Sales1.62 Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book2.74Miscellaneous Outstanding Shares10,540,000Free Float10,112,000Market Cap$23.08 million OptionableNot Optionable Beta1.30 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Robert BanksPresident, CEO & DirectorMs. Judy F. Krandel C.F.A. (Age 59)Chief Financial Officer Mr. Alfred VargasDirector of OperationsBrianne McGuireDirector of Brand, Marketing & Business DevelopmentVashone R. ThomasVice President of Quality, Regulatory, & Human ResourcesMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Executive Officer of Specialty Renal Products, Inc Comp: $300.18kMr. Greg LucasPresident of Aether Water SystemsMs. Judy MazziniControllerMore ExecutivesKey CompetitorsPolyPidNASDAQ:PYPDInspira Technologies Oxy B.H.N.NASDAQ:IINNGlucoTrackNASDAQ:GCTKAkiliNASDAQ:AKLISTRATA Skin SciencesNASDAQ:SSKNView All CompetitorsInsidersRobert R Jr. BanksBought 18,000 shares on 12/7/2023Total: $39,600.00 ($2.20/share)Robert R Jr. BanksBought 99 shares on 8/14/2023Total: $148.50 ($1.50/share)View All Insider Transactions NEPH Stock Analysis - Frequently Asked Questions How have NEPH shares performed in 2024? Nephros' stock was trading at $3.46 at the beginning of 2024. Since then, NEPH stock has decreased by 36.7% and is now trading at $2.19. View the best growth stocks for 2024 here. Are investors shorting Nephros? Nephros saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 1,600 shares, a decline of 38.5% from the March 31st total of 2,600 shares. Based on an average daily volume of 18,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are sold short. View Nephros' Short Interest. When is Nephros' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our NEPH earnings forecast. How were Nephros' earnings last quarter? Nephros, Inc. (NASDAQ:NEPH) released its quarterly earnings results on Thursday, March, 7th. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $3.25 million for the quarter. Nephros had a negative trailing twelve-month return on equity of 18.25% and a negative net margin of 11.06%. How do I buy shares of Nephros? Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEPH) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsThe World's First "$20 Trillion Drug?"Behind the MarketsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.